Precision Treatment in ACS-Role of Assessing Fibrinolysis

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Apr 3

PMID 33804303

Citations 1

Authors

Ying X Gue

Young-Hoon Jeong

Mohamed Farag

Nikolaos Spinthakis

Diana A Gorog

Affiliations

Soon will be listed here.

Abstract

Despite advancements in pharmacotherapy and interventional strategies, patients with acute coronary syndrome (ACS) remain at risk of recurrent thrombotic events. In addition to an enhanced tendency to thrombus formation, impairment in the ability to naturally dissolve or lyse a developing thrombus, namely impaired endogenous fibrinolysis, is responsible for a major part of this residual risk regardless of optimal antiplatelet medication. Global assessment of endogenous fibrinolysis, including a point-of-care assay, can identify patients with ACS at persistent high cardiovascular risk and might play an important role in allowing the personalisation of potent antithrombotic therapy to enhance fibrinolytic status, providing precision treatment of ACS to improve long-term outcome.

Citing Articles

Intravascular Lithotripsy as a Novel Treatment Method for Calcified Unprotected Left Main Diseases-Comparison to Rotational Atherectomy-Short-Term Outcomes.

Rola P, Kulczycki J, Wlodarczak A, Barycki M, Wlodarczak S, Szudrowicz M Int J Environ Res Public Health. 2022; 19(15).

PMID: 35897381 PMC: 9330248. DOI: 10.3390/ijerph19159011.

References

Gorog D . Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease. J Am Coll Cardiol. 2010; 55(24):2701-9. DOI: 10.1016/j.jacc.2009.11.095. View

Spinthakis N, Farag M, Rocca B, Gorog D . More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. J Am Heart Assoc. 2018; 7(3). PMC: 5850258. DOI: 10.1161/JAHA.117.007754. View

Bayes-Genis A, Mateo J, Santalo M, Oliver A, Guindo J, Badimon L . D-Dimer is an early diagnostic marker of coronary ischemia in patients with chest pain. Am Heart J. 2000; 140(3):379-84. DOI: 10.1067/mhj.2000.108823. View

Farag M, Niespialowska-Steuden M, Okafor O, Artman B, Srinivasan M, Khan A . Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation. Platelets. 2016; 27(7):687-693. DOI: 10.3109/09537104.2016.1158402. View

Ridker P, Everett B, Thuren T, MacFadyen J, Chang W, Ballantyne C . Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017; 377(12):1119-1131. DOI: 10.1056/NEJMoa1707914. View

Saraf S, Christopoulos C, Ben Salha I, Stott D, Gorog D . Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction. J Am Coll Cardiol. 2010; 55(19):2107-15. DOI: 10.1016/j.jacc.2010.01.033. View

Gurbel P, Erlinge D, Ohman E, Neely B, Neely M, Goodman S . Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA. 2012; 308(17):1785-94. DOI: 10.1001/jama.2012.17312. View

Eikelboom J, Connolly S, Bosch J, Dagenais G, Hart R, Shestakovska O . Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017; 377(14):1319-1330. DOI: 10.1056/NEJMoa1709118. View

Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H . Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002; 347(13):969-74. DOI: 10.1056/NEJMoa020496. View

10.

Aday A, Ridker P . Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease. Front Cardiovasc Med. 2019; 6:16. PMC: 6403155. DOI: 10.3389/fcvm.2019.00016. View

11.

Spinthakis N, Farag M, Gue Y, Srinivasan M, Wellsted D, Gorog D . Effect of P2Y inhibitors on thrombus stability and endogenous fibrinolysis. Thromb Res. 2018; 173:102-108. DOI: 10.1016/j.thromres.2018.11.023. View

12.

Angiolillo D, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass T . Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007; 49(14):1505-16. DOI: 10.1016/j.jacc.2006.11.044. View

13.

Undas A . Fibrin clot properties and their modulation in thrombotic disorders. Thromb Haemost. 2014; 112(1):32-42. DOI: 10.1160/TH14-01-0032. View

14.

Roth C, Krychtiuk K, Gangl C, Schrutka L, Distelmaier K, Wojta J . Lipoprotein(a) plasma levels are not associated with survival after acute coronary syndromes: An observational cohort study. PLoS One. 2020; 15(1):e0227054. PMC: 6952077. DOI: 10.1371/journal.pone.0227054. View

15.

Libby P, Simon D . Inflammation and thrombosis: the clot thickens. Circulation. 2001; 103(13):1718-20. DOI: 10.1161/01.cir.103.13.1718. View

16.

Ibanez B, James S, Agewall S, Antunes M, Bucciarelli-Ducci C, Bueno H . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European.... Eur Heart J. 2017; 39(2):119-177. DOI: 10.1093/eurheartj/ehx393. View

17.

Pineda J, Marin F, Marco P, Roldan V, Valencia J, Ruiz-Nodar J . Premature coronary artery disease in young (age <45) subjects: interactions of lipid profile, thrombophilic and haemostatic markers. Int J Cardiol. 2008; 136(2):222-5. DOI: 10.1016/j.ijcard.2008.04.020. View

18.

French J, Burgess S, Chew D . Re-infarction after primary percutaneous coronary intervention. Curr Opin Cardiol. 2015; 30(4):354-8. DOI: 10.1097/HCO.0000000000000193. View

19.

Akkus M, Polat G, Yurtdas M, Akcay B, Ercetin N, Cicek D . Admission levels of C-reactive protein and plasminogen activator inhibitor-1 in patients with acute myocardial infarction with and without cardiogenic shock or heart failure on admission. Int Heart J. 2009; 50(1):33-45. DOI: 10.1536/ihj.50.33. View

20.

Kinlay S, Schwartz G, Olsson A, Rifai N, Bao W, Libby P . Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study. Atherosclerosis. 2009; 206(2):551-5. DOI: 10.1016/j.atherosclerosis.2009.03.020. View